Haemonetics (HAE) Cash from Investing Activities (2009 - 2026)

Haemonetics' Cash from Investing Activities history runs 18 years deep, the most recent figure standing at -$86.6 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 580.12% year-over-year to -$86.6 million in Q1 2026; TTM through Mar 2026 was -$179.5 million, a 10.9% decrease from a year earlier, with the FY2026 full-year figure at -$179.5 million, down 10.9% from the prior year.
• Cash from Investing Activities declined to -$86.6 million in Q1 2026 per HAE's latest filing, from -$29.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $18.0 million in Q1 2025 and bottomed at -$268.9 million in Q4 2023.
• The 5-year median for Cash from Investing Activities is -$30.0 million (2025), against an average of -$47.6 million.
• Across the five-year window, Cash from Investing Activities sank 812.11% in 2024 and jumped 238.17% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$36.5 million in 2022, then plunged by 636.81% to -$268.9 million in 2023, then soared by 93.54% to -$17.4 million in 2024, then tumbled by 69.63% to -$29.5 million in 2025, then tumbled by 193.94% to -$86.6 million in 2026.
• Per Business Quant, the three latest HAE Cash from Investing Activities figures stand at -$86.6 million (Q1 2026), -$29.5 million (Q4 2025), and -$30.5 million (Q3 2025).